Medical News Today -
19 Sep 2013 10:00
Boehringer Ingelheim Pharmaceuticals, Inc. have announced the FDA has granted Breakthrough Therapy designation to volasertib*, an investigational inhibitor of polo-like kinase (Plk), being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia (AML), ineligible for intensive remission induction therapy...
Share this Article